FSD Pharma Inc. is a publicly-traded holding company, since May 2018.
FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicronized-palmitoylethanolamide (“FSD201”), by down-regulating the cytokines to effectuate an anti-inflammatory response.
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
Director Interviews
FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end 2020 as it files IND
Director Interviews
FSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial
